People · Operator
Named in public records as an officer, director or promoter · active 2019–2021 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Precision IBD, Inc. | — | Biotechnology | Series C | $111.8M | $1.8B | 2019 |
| GLO Pharma, Inc. | — | Pharmaceuticals | Series C | $60.4M | $1.2B | 2021 |
Douglas Wall at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Douglas Wall on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Lauren Otsuki | 2 | 4 |
| Scott L. Glenn | 1 | 9 |
| Gerald T. Proehl | 1 | 5 |
| Brent Saunders | 1 | 5 |
| Scott Glenn | 1 | 4 |
| Nicole Quinn | 1 | 4 |
| Lauren G. Otsuki | 1 | 3 |
| Shierley Widjaja | 1 | 3 |
| Shlomo Melmed | 1 | 3 |
| Todd Jackson | 1 | 2 |
| Gregory Behar | 1 | 2 |
| Tadataka Yamada, M.D. | 1 | 2 |
| MARK MCKENNA | 1 | 2 |
| James Laur | 1 | 2 |
| Fabian Seelbach | 1 | 1 |
| Maureen Case | 1 | 1 |
| Marla Beck | 1 | 1 |
| Jana Messersmith | 1 | 1 |
| Carol Shen | 1 | 1 |
| Vimla Black-Gupta | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.